Clinical outcomes are complex and often involve multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical outcomes, imaging inspections, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnostics and treatment programs. Treatment and management of the treatment of pulmonary inflammation require individual development, typically including drug therapy, rehabilitation interventions, and regular follow-up multidimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatoid immunodeficiency disorders that were previously difficult to treat have been significantly improved.
Treatment requires close monitoring of therapeutic efficacy and adverse reactions, adapting to timely regimens according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of pulmonary fibrosis. The platform serves the China International Medical Service System, a team of nationally and internationally authoritative experts in the field of autoimmune and rheumatoid immunity, who provide the following services to patients: 1.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.